EGFR and non-small cell lung carcinoma: First and second-generation EGFR TKIs, including erlotinib, gefitinib and afatinib, have been shown to prolong PFS, increase clinical response, and relieve clinical symptoms compared with standard chemotherapy for patients with advanced NSCLC expressing mutant EGFR in the first-line setting [3–5].